Tyche Industries Limited , a prominent player in the Indian pharmaceutical sector, has commenced its dividend distribution for the financial year 2024-25. The company has declared a dividend of 30% on the face value of its equity shares, translating to Rs 3.00 per share.

Dividend Details

The dividend payments, which began on October 10, 2025, are being distributed to shareholders whose names appeared on the company's register of members as of the record date, September 19, 2025.

Official Communication

In an official communication to the BSE Limited on October 14, 2025, Tyche Industries confirmed the initiation of the dividend payout. Pradosh Ranjan Jena, the Company Secretary & Compliance Officer, stated in the letter, "The Company has started the payment of the Dividend for the financial year 2024-25 from 10th October, 2025 to all the members whose name appear on the Register of members as on the record date i.e., 19th September 2025."

This dividend declaration demonstrates Tyche Industries' commitment to delivering value to its shareholders. It also reflects the company's financial performance and its policy of sharing profits with investors.

Shareholders of Tyche Industries Limited can expect to receive their dividend payments through their registered payment methods. Those who haven't yet received their dividends may want to ensure their bank details are up to date with their respective depository participants or the company's registrar.

As always, investors are advised to consider dividend announcements as part of their overall investment strategy and to consult with financial advisors for personalized advice.

Tyche Industries Limited , a prominent player in the pharmaceutical sector, has announced significant changes to its leadership structure following the company's 27th Annual General Meeting (AGM) held on September 30, 2025. The reshuffling marks a new chapter in the company's governance and strategic direction.

Key Leadership Changes

The shareholders approved several pivotal appointments and changes in designations:

1. New Managing Director: Sandeep Gokaraju has been appointed as the Managing Director for a five-year term, effective September 5, 2025. Mr. Gokaraju, a qualified engineer with a B.Tech in Chemical Engineering and an MBA, brings over 12 years of experience in pharmaceutical marketing, product development, and overall management to his new role.

2. Executive Director Appointments:

   • G Ganesh Kumar, previously the Chairman and Managing Director, has transitioned to the role of Executive Director.
   • Satya Srinivas Uppalapati joins the board as an Executive Director, bringing more than 30 years of experience in pharmaceutical marketing and product development.

3. Independent Directors:

   • Srinivas Gelli's designation has changed from Non-Executive Director to Non-Executive Independent Director.
   • Penumatsa Vijaya Lakshmi has been re-appointed as an Independent Director for a second five-year term.

Board Composition and Expertise

The newly structured board brings a diverse set of skills and experiences:

• Sandeep Gokaraju and G Ganesh Kumar, who are brothers, will lead the company's operations and strategy. G Ganesh Kumar holds a Master of Business degree from the USA and has over 20 years of experience in production and administration.
• Satya Srinivas Uppalapati, a B.Tech in Mechanical Engineering, adds substantial expertise in pharmaceutical marketing and product development.
• Srinivas Gelli, a Chartered Accountant and Cost Accountant, brings over 20 years of experience in accounting and finance.
• Penumatsa Vijaya Lakshmi, with an MBA, contributes 14 years of experience in accounting and finance.

Additional AGM Approvals

The AGM also saw the approval of other significant matters:

• A dividend of 30% (Rs. 3.00 per share) was declared for the financial year ended March 31, 2025.
• Mrs. D. Renuka, a practicing Company Secretary, was appointed as the Secretarial Auditor for a term of five consecutive financial years from 2025-26 to 2029-30.
• The remuneration for the Cost Auditor, Mr. Sativada Venkat Rao, for the financial year 2025-26 was approved.

Governance and Compliance

Tyche Industries has ensured compliance with SEBI regulations and corporate governance norms. The AGM was conducted through video conferencing, adhering to the guidelines set by the Ministry of Corporate Affairs and SEBI in light of the ongoing global situation.

The strategic leadership restructuring reflects Tyche Industries' commitment to leveraging diverse expertise for future growth and maintaining strong corporate governance practices. The blend of family leadership and independent directors aims to balance continuity with fresh perspectives in the company's decision-making process.